Drug Induced Liver Injury (DILI) Conference XV: The Importance of Getting it Right

Wednesday, March 18, 2015 –
Thursday, March 19, 2015
7:30 AM – 3:30 PM

Marriott Inn & Conference Center
University of Maryland
University College
3501 University Blvd.
East Hyattsville, Maryland 20783
(301) 985-7300

U.S. Food and Drug Administration (FDA)
Critical Path Institute

How to measure and interpret DILI information and make correct diagnoses

Serious drug-induced liver injury (SDILI) is a major problem for drug development and clinical care.  Key information used in detection of liver injury caused by drugs includes serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), plus total bilirubin (TBL) concentration. Time courses of changes of variables in selected patients, and a well-constructed clinical narrative help greatly. This academic-industry-government international conference will discuss new findings and thinking about DILI, including presentations by experts in clinical hepatology, toxicology, and other fields, and lively discussions with all registrants.  We look forward to your participation!

Organizers: John R. Senior and Lana Pauls

The program is co-sponsored by the Food and Drug Administration/Center for Drug Evaluation and Research (FDA/CDER), the Critical Path Institute (C-Path), and the Pharmaceutical Research and Manufacturers of America (PhRMA). The program is endorsed by the National Institutes of Health (NIH) the Drug-Induced Liver Injury Network (DILIN), and the American Association for the Study of Liver Diseases (AASLD).